Capromab - Cytogen Corporation

Drug Profile

Capromab - Cytogen Corporation

Alternative Names: 111In CYT 356; Capromab pendetide; CYT 356; indium (111In) labeled capromab pendetide; ProstaScint

Latest Information Update: 13 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytogen Corporation
  • Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 06 Jun 2016 Hybridyne Imaging Technologies initiates enrolment in a clinical trial in Prostate cancer (Diagnosis) in Canada
  • 02 Mar 2016 Hybridyne Imaging Technologies plans a clinical trial for diagnosis in Prostate cancer in Canada
  • 09 Jun 2015 Aytu Biosciences in-licenses capromab from Jazz Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top